LMLino Möhrmann

Lino Möhrmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lino Möhrmann has a total of 273 co-authors. Here are the top co-authors by number of shared publications:

  • Christoph E. Heilig

    Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany

    13 shared publications
  • Dorothea Hanf

    Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT), NCT Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Germany; Translational Medical Oncology, Faculty of Medicine, and University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany; German Cancer Consortium (DKTK), Dresden, Germany

    13 shared publications
  • Evelin Schröck

    13 shared publications
  • Martina Fröhlich

    Computational Oncology Group (CO), Molecular Precision Oncology Program (MPOP), German Cancer Research Center (DKFZ), Heidelberg, Germany; National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany

    13 shared publications
  • Peter Horak

    NCT Heidelberg

    13 shared publications
  • Albrecht Stenzinger

    Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany

    12 shared publications

Latest Publications

  • Open Access

    On-premise medical AI agents for reliable clinical decision-making

    by Li Zhang, Georg Wölflein, Dyke Ferber, Junhao Liang, Zunamys I. Carrero, Xuewei Wu, Julien Vibert, Jan Clusmann, Lino Möhrmann, Elena E. Möhrmann, et al.

    Autonomous clinical artificial intelligence (AI) agents powered by large language models (LLMs), meaning systems that can complete a diagnostic workflow without continuous human input, are increasingly capable of supporting complex reasoning and decision-making. Clinical translation, however, remains limited by two unmet requirements: institutionally governed deployment and reliable decision-time uncertainty estimation. Here we developed and evaluated a fully on-premise clinical agent that couples local operational control with a multi-perspective reliability framework to support selective autonomy. Across two Medical Information Mart for Intensive Care IV (MIMIC-IV)-derived benchmarks, the agent achieved 90.04% accuracy on a seven-disease task and 83.8% accuracy on a four-disease task, approaching a cloud baseline on the primary benchmark. To assess decision-time reliability, we quantified internal-likelihood, language-based and behavioral-stability measures for diagnosis and reasoning. Diagnostic behavioral consistency provided the strongest discrimination of correctness (area under the curve (AUC) = 0.860) and remained informative under stress testing (AUC = 0.875). At a consistency threshold of 0.90, 49.4% of cases were retained at 98.9% diagnostic accuracy. These findings support a practical framework for institutionally governed clinical agents in which decision-time reliability signals identify a lower-risk subset for autonomous handling and defer the remainder for review.


  • Open Access

    Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors

    by Lino Möhrmann, Lysann Rostock, Maximilian Werner, Małgorzata Oleś, Jonas S. Arnold, Nagarajan Paramasivam, Korinna Jöhrens, Luise Rupp, Marc Schmitz, Daniela Richter, et al.


  • Open Access

    Translational and clinical comparison of whole genome and transcriptome to panel sequencing in precision oncology

    by Irina A Kerle, Thomas Gross, Anja Kögler, Jonas S Arnold, Maximilian Werner, Jan-Niklas Eckardt, Elena E Möhrmann, Marie Arlt, Barbara Hutter, Jennifer Hüllein, et al.

    Precision oncology offers new cancer treatment options, yet sequencing methods vary in type and scope. In this study, we compared whole-exome/whole-genome (WES/WGS) and transcriptome sequencing (TS) with broad panel sequencing by resequencing the same tumor DNA and RNA as well as normal tissue DNA for germline assessment, from 20 patients with rare or advanced tumors, who were originally sequenced by WES/WGS ± TS within the DKFZ/NCT/DKTK MASTER program from 2015 to 2020. Molecular analyses resulted in a median number of 2.5 (gene panel) to 3.5 (WES/WGS ± TS) treatment recommendations per patient. Our results showed that approximately half of the therapy recommendations (TRs) of both sequencing programs were identical, while approximately one-third of the TRs in WES/WGS ± TS relied on biomarkers not covered by the panel. Eight of 10 molecularly informed therapy implementations were supported by the panel, the remaining two were based on biomarkers absent from the panel, highlighting the potential additional clinical benefit of WGS and TS.


  • Open Access

    NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology

    by Andreas Mock, Maria-Veronica Teleanu, Simon Kreutzfeldt, Christoph E. Heilig, Jennifer Hüllein, Lino Möhrmann, Arne Jahn, Dorothea Hanf, Irina A. Kerle, Hans Martin Singh, et al.

    Analysis of selected cancer genes has become an important tool in precision oncology but cannot fully capture the molecular features and, most importantly, vulnerabilities of individual tumors. Observational and interventional studies have shown that decision-making based on comprehensive molecular characterization adds significant clinical value. However, the complexity and heterogeneity of the resulting data are major challenges for disciplines involved in interpretation and recommendations for individualized care, and limited information exists on how to approach multilayered tumor profiles in clinical routine. We report our experience with the practical use of data from whole-genome or exome and RNA sequencing and DNA methylation profiling within the MASTER (Molecularly Aided Stratification for Tumor Eradication Research) program of the National Center for Tumor Diseases (NCT) Heidelberg and Dresden and the German Cancer Research Center (DKFZ). We cover all relevant steps of an end-to-end precision oncology workflow, from sample collection, molecular analysis, and variant prioritization to assigning treatment recommendations and discussion in the molecular tumor board. To provide insight into our approach to multidimensional tumor profiles and guidance on interpreting their biological impact and diagnostic and therapeutic implications, we present case studies from the NCT/DKFZ molecular tumor board that illustrate our daily practice. This manual is intended to be useful for physicians, biologists, and bioinformaticians involved in the clinical interpretation of genome-wide molecular information.


  • Response to (K)RASG12C and EGFR Inhibition in a Patient With NRASG12C-Mutated Rectal Cancer

    by Lino Möhrmann, Ani Cuberi, Sascha Brückmann, Sebastian Stasik, Lukas C. Heukamp, Martin Bornhäuser, Hanno Glimm, Gunnar Folprecht


  • Open Access

    Data from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

    by Peter Horak, Christoph Heining, Simon Kreutzfeldt, Barbara Hutter, Andreas Mock, Jennifer Hüllein, Martina Fröhlich, Sebastian Uhrig, Arne Jahn, Andreas Rump, et al.

    The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients (rare cancers, 75.5%) enrolled in a prospective observational study by the German Cancer Consortium that applies whole-genome/exome and RNA sequencing to inform the care of adults with incurable cancers. On the basis of 472 single and six composite biomarkers, a cross-institutional molecular tumor board provided evidence-based management recommendations, including diagnostic reevaluation, genetic counseling, and experimental treatment, in 88% of cases. Recommended therapies were administered in 362 of 1,138 patients (31.8%) and resulted in significantly improved overall response and disease control rates (23.9% and 55.3%) compared with previous therapies, translating into a progression-free survival ratio >1.3 in 35.7% of patients. These data demonstrate the benefit of molecular stratification in rare cancers and represent a resource that may promote clinical trial access and drug approvals in this underserved patient population.Significance:Rare cancers are difficult to treat; in particular, molecular pathogenesis–oriented medical therapies are often lacking. This study shows that whole-genome/exome and RNA sequencing enables molecularly informed treatments that lead to clinical benefit in a substantial proportion of patients with advanced rare cancers and paves the way for future clinical trials.See related commentary by Eggermont et al., p. 2677.This article is highlighted in the In This Issue feature, p. 2659

  • Open Access

    Supplementary Tables S1-S7 from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

    by Peter Horak, Simon Kreutzfeldt, Barbara Hutter, Andreas Mock, Jennifer Hüllein, Martina Fröhlich, Sebastian Uhrig, Arne Jahn, Andreas Rump, Laura Gieldon, et al.

    This excel file contains supplementary tables S1-S7.

  • Open Access

    Supplementary Methods from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

    by Peter Horak, Simon Kreutzfeldt, Barbara Hutter, Andreas Mock, Jennifer Hüllein, Martina Fröhlich, Sebastian Uhrig, Arne Jahn, Andreas Rump, Laura Gieldon, et al.

    This file contains supplementary methods and references.


  • Open Access

    Supplementary Figures S1-S10 from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

    by Peter Horak, Christoph Heining, Simon Kreutzfeldt, Barbara Hutter, Andreas Mock, Jennifer Hüllein, Martina Fröhlich, Sebastian Uhrig, Arne Jahn, Andreas Rump, et al.

    This file contains supplementary figures S1-S10.

  • Open Access

    Data from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

    by Peter Horak, Christoph Heining, Simon Kreutzfeldt, Barbara Hutter, Andreas Mock, Jennifer Hüllein, Martina Fröhlich, Sebastian Uhrig, Arne Jahn, Andreas Rump, et al.

    The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients (rare cancers, 75.5%) enrolled in a prospective observational study by the German Cancer Consortium that applies whole-genome/exome and RNA sequencing to inform the care of adults with incurable cancers. On the basis of 472 single and six composite biomarkers, a cross-institutional molecular tumor board provided evidence-based management recommendations, including diagnostic reevaluation, genetic counseling, and experimental treatment, in 88% of cases. Recommended therapies were administered in 362 of 1,138 patients (31.8%) and resulted in significantly improved overall response and disease control rates (23.9% and 55.3%) compared with previous therapies, translating into a progression-free survival ratio >1.3 in 35.7% of patients. These data demonstrate the benefit of molecular stratification in rare cancers and represent a resource that may promote clinical trial access and drug approvals in this underserved patient population.Significance:Rare cancers are difficult to treat; in particular, molecular pathogenesis–oriented medical therapies are often lacking. This study shows that whole-genome/exome and RNA sequencing enables molecularly informed treatments that lead to clinical benefit in a substantial proportion of patients with advanced rare cancers and paves the way for future clinical trials.See related commentary by Eggermont et al., p. 2677.This article is highlighted in the In This Issue feature, p. 2659